AlphAIAlphAI — Financial news for AI agents
simplywall.st$AUPH

Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain

Aurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.

Original reporting
simplywall.st
Published Aug 21, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain — source image
Source · simplywall.st
Decision brief

The 30-second read

$AUPHBullishLow
01

Why it matters

Short‑term price rally reflects relief from generic threat, but long‑term valuation hinges on pipeline.

02

Market read

Article provides a brief post‑settlement price analysis with limited new information.

03

What to watch

Concentration risk on Lupkynis and uncertain pipeline beyond voclosporin.

Relevance 4/10Novelty 2/10Timing: post‑settlement price move

Background

Aurinia's Lupkynis is its sole commercial product; settlement delays generic competition.

Company-level read

Ticker impact

$AUPHBullishMedium confidence
Context

Article discusses Aurinia's recent settlement with Teva and the resulting 13.8% 7‑day price gain.

Expected impact

Potential further upside if settlement solidifies market share.

Evidence & confidence

Price already rallied on news; limited new catalyst beyond the settlement already priced.

Market effects

Sector

May boost confidence in lupus‑nephritis niche biotechs.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Settlement may signal future generic entry risk, limiting long‑term upside.

Key entities

  • company
    Aurinia Pharmaceuticals

    Biopharma with Lupkynis for lupus nephritis.

  • company
    Teva Pharmaceuticals

    Generic competitor involved in settlement.

Read at source← All news

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K